ADAR1 Capital Management, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001940272

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q3 2024 · 262 positions · Total reported value $483.90M · Top-10 concentration 52.8% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 47.5% · 33 new · 62 cut · 48 exited

Active Share (vs S&P 500): 98.9% · vs QQQ: 99.4% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -7.0% · vs SPY -9.1% · Prev Value $1.81B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -3.7% · vs SPY -5.9% · Latest Value $1.82B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2024 13F filing, ADAR1 Capital Management, LLC disclosed 262 equity positions with a combined reported value of $483.90M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 52.8% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2024 were PTGX ($44.16M), BBIO ($36.88M), BOXX ($35.23M). By sector, the heaviest allocations are Health Care 76.6%, Technology 0.1%. Versus the prior quarter, allocation shifted toward Health Care (+2.0pp) and away from Other (-1.7pp).

Versus the prior quarter, ADAR1 Capital Management, LLC opened 33 new positions, trimmed 62 and fully exited 48, a turnover rate of 47.5% of positions. The portfolio's overlap with the prior quarter was 51% of names.

The largest new positions opened in Q3 2024 were ZURA ($15.31M), AAM ($10.12M), XNCR ($6.88M).

Of the 48 positions fully exited versus the prior quarter, the largest were QURE ($5.48M), SPY ($4.35M), ACST ($2.80M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2024)

  • ZURA ZURA BIO LTD · $15.31M
  • AAM AA MISSION · $10.12M
  • XNCR XENCOR INC · $6.88M
  • BIIB BIOGEN INC · $5.74M
  • XBI SPDR SERIES TRUST · $3.95M
  • DNTH DIANTHUS THERAPEUTICS INC · $3.25M
  • GRCE GRACE THERAPEUTICS INC · $2.88M
  • PIRS PIERIS PHARMACEUTICALS INC · $2.40M

Fully Exited (vs previous quarter)

  • QURE UNIQURE NV · prev qtr: $5.48M
  • SPY STATE STR SPDR S&P 500 ETF T · prev qtr: $4.35M · history
  • ACST ACASTI PHARMA INC · prev qtr: $2.80M
  • VUSB VANGUARD BD INDEX FDS · prev qtr: $2.73M
  • JPST J P MORGAN EXCHANGE TRADED F · prev qtr: $2.73M
  • SHV ISHARES TR · prev qtr: $2.71M
  • CERE CEREVEL THERAPEUTICS HLDNG I · prev qtr: $2.05M
  • ULST SSGA ACTIVE ETF TR · prev qtr: $1.93M

Insider Transactions (Form 4)

Latest ADAR1 Capital Management, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-11 Buy NextCure, Inc. 12,333 $5.10 SEC filing
2026-11-06 Buy NextCure, Inc. 3,662 $5.10 SEC filing
2026-11-05 Buy InMed Pharmaceuticals Inc. 2,640 $13.10 SEC filing
2026-11-05 Buy NextCure, Inc. 1,024 $5.10 SEC filing
2026-10-27 Buy NextCure, Inc. 3,553 $5.10 SEC filing
2026-10-26 Buy NextCure, Inc. 1,672 $5.03 SEC filing
2026-10-23 Buy InMed Pharmaceuticals Inc. 4 $1.32 SEC filing
2026-10-23 Buy NextCure, Inc. 5,626 $4.83 SEC filing

All insider transactions →

Fund Profile

ADAR1 Capital Management, LLC is an SEC-registered 13F filer based in Austin, TX, United States. As of Q2 2026 it reported 268 US equity positions with a combined value of $1.81B. HoldingsHub carries 11 quarters of its filings (Q4 2023–Q2 2026).

Firm Snapshot

  • Headquarters: AUSTIN, TX, United States
  • SEC registration: 801-130082 (status: Approved), registered 2024-04-25
  • Regulatory AUM (Form ADV): $1.68B as of 2026-03-31
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 268 positions · $1.81B reported value (Q2 2026)
  • Top 10 holdings = 34.2% of reported value
  • Largest position: PTGX (PROTAGONIST THERAPEUTICS INC) at 6.5%
  • Average position size: $6.74M

Sector Tilt

  • Health Care 86.5%
  • Financials 2.6%
  • Industrials 0.4%
  • (classified holdings cover 90% of value)

Quarterly Activity

  • Q2 2026: 42 new, 99 added, 60 reduced, 69 exited
  • 67 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 76.6%
Technology 0.1%
Utilities 0.1%
Materials 0.1%
Energy 0.0%
Other 22.9%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 981.29K $44.16M 9.12%
9.12%
Reduce
2 1.45M $36.88M 7.62%
7.62%
Add
3 323.38K $35.23M 7.28%
7.28%
Reduce
4 3.03M $34.91M 7.21%
7.21%
Reduce
5 1.10M $31.02M 6.41%
6.41%
Reduce
6 161.40K $24.10M 4.98%
4.98%
Add
7 3.77M $15.31M 3.16%
3.16%
New
8 532.45K $12.85M 2.66%
2.66%
Add
9 436.67K $10.91M 2.25%
2.25%
Add
10 1.01M $10.12M 2.09%
2.09%
New
11 729.40K $8.83M 1.82%
1.82%
Add
12 2.09M $8.04M 1.66%
1.66%
Reduce
13 1.15M $7.98M 1.65%
1.65%
Reduce
14 153.29K $7.66M 1.58%
1.58%
Add
15 1.57M $7.62M 1.57%
1.57%
Reduce
16 750.00K $7.51M 1.55%
1.55%
Hold
17 342.26K $6.88M 1.42%
1.42%
New
18 192.72K $6.46M 1.33%
1.33%
Add
19 521.61K $6.01M 1.24%
1.24%
Add
20 29.62K $5.74M 1.19%
1.19%
New
21 1.34M $5.66M 1.17%
1.17%
Add
22 143.10K $5.40M 1.12%
1.12%
Add
23 88.42K $4.52M 0.93%
0.93%
Add
24 404.14K $4.22M 0.87%
0.87%
Hold
25 40.00K $3.95M 0.82%
0.82%
New
26 127.16K $3.85M 0.80%
0.80%
Reduce
27 376.74K $3.85M 0.80%
0.80%
Add
28 1.01M $3.84M 0.79%
0.79%
Reduce
29 122.81K $3.51M 0.72%
0.72%
Add
30 57.18K $3.36M 0.69%
0.69%
Add
31 118.74K $3.25M 0.67%
0.67%
New
32 742.63K $3.15M 0.65%
0.65%
Add
33 101.83K $2.97M 0.61%
0.61%
Add
34 959.57K $2.88M 0.59%
0.59%
New
35 64.25K $2.87M 0.59%
0.59%
Reduce
36 246.13K $2.76M 0.57%
0.57%
Add
37 557.16K $2.53M 0.52%
0.52%
Add
38 144.64K $2.40M 0.50%
0.50%
New
39 319.19K $2.39M 0.49%
0.49%
Add
40 1.02M $2.19M 0.45%
0.45%
Add
41 74.43K $2.08M 0.43%
0.43%
Reduce
42 105.00K $2.02M 0.42%
0.42%
New
43 44.35K $2.01M 0.42%
0.42%
New
44 21.79K $2.00M 0.41%
0.41%
Reduce
45 428.80K $2.00M 0.41%
0.41%
Add
46 108.17K $1.95M 0.40%
0.40%
Add
47 306.07K $1.74M 0.36%
0.36%
Hold
48 49.45K $1.65M 0.34%
0.34%
Add
49 302.21K $1.63M 0.34%
0.34%
New
50 23.71K $1.60M 0.33%
0.33%
New

FAQ

What did ADAR1 Capital Management, LLC buy in 2024-Q3?

In its 2024-Q3 13F filing, ADAR1 Capital Management, LLC reported 262 equity positions worth $483.90M in aggregate; its largest disclosed positions were PTGX ($44.16M), BBIO ($36.88M), BOXX ($35.23M).

How large is ADAR1 Capital Management, LLC's portfolio?

ADAR1 Capital Management, LLC reported $483.90M of long equity holdings across 262 positions as of 2024-Q3. Top-10 holdings account for 52.8% of reported value.

What is ADAR1 Capital Management, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/adar1-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →